Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. (Q40459857)
Jump to navigation
Jump to search
scientific article published on January 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. |
scientific article published on January 2007 |
Statements
1 reference
Dose-adjusted EPOCH plus rituximab is an effective regimen in patients with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study. (English)
1 reference
Dunia De Miguel
1 reference
Carmen Burgaleta
1 reference
Julio García-Suárez
1 reference
Helena Bañas
1 reference
Ignacio Arribas
1 reference
Teresa Pascual
1 reference
1 January 2007
1 reference
1 reference
136
1 reference
2
1 reference
276-285
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference